User login
Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.
Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.
Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.
Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.
Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005.
Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.
Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.
Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.
Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.
Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005.
Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.
Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.
Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.
Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.
Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005.